Hillsdale Investment Management Inc. Acquires 13,120 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Hillsdale Investment Management Inc. boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 8.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 166,300 shares of the company’s stock after acquiring an additional 13,120 shares during the period. Hillsdale Investment Management Inc. owned 0.18% of Myriad Genetics worth $2,280,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. State Street Corp raised its position in shares of Myriad Genetics by 8.3% in the third quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after purchasing an additional 359,685 shares during the period. Disciplined Growth Investors Inc. MN raised its holdings in Myriad Genetics by 21.1% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after acquiring an additional 440,107 shares during the period. Sei Investments Co. lifted its position in Myriad Genetics by 7.4% during the fourth quarter. Sei Investments Co. now owns 2,526,761 shares of the company’s stock worth $34,642,000 after acquiring an additional 174,770 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Myriad Genetics by 153.7% during the third quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock worth $59,973,000 after acquiring an additional 1,326,497 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Myriad Genetics by 1.0% in the third quarter. Geode Capital Management LLC now owns 2,154,035 shares of the company’s stock valued at $59,010,000 after purchasing an additional 21,220 shares during the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Ratings Changes

MYGN has been the topic of a number of research reports. Stephens reaffirmed an “equal weight” rating and issued a $20.00 price objective on shares of Myriad Genetics in a report on Thursday, January 16th. UBS Group decreased their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 25th. StockNews.com downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, March 13th. The Goldman Sachs Group reduced their price target on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Piper Sandler upgraded Myriad Genetics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $11.50 to $12.50 in a research note on Wednesday, March 12th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $21.89.

Myriad Genetics Trading Up 1.0 %

Shares of Myriad Genetics stock opened at $10.01 on Friday. The firm’s 50 day moving average is $12.14 and its 200 day moving average is $17.11. The firm has a market capitalization of $914.00 million, a PE ratio of -7.70 and a beta of 1.79. Myriad Genetics, Inc. has a 1 year low of $9.36 and a 1 year high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. During the same quarter in the previous year, the business posted ($0.12) EPS. Equities research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.